NCT00801684 - ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

July 31, 2009

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Placebo

Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.

DRUG

TrIP-2D

Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

DRUG

TrIP-2SS

Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

DRUG

TrIP-2D

Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

DRUG

TrIP-2SS + Foradil

Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.

Trial Locations (1)

29303

Spartanburg Medical Research, Spartanburg